血栓心脉宁胶囊联合单唾液酸四己糖神经节苷脂治疗脑梗死的临床研究

目的探讨血栓心脉宁胶囊联合单唾液酸四己糖神经节苷脂治疗脑梗死的临床效果。方法收集2015年9月—2016年9月在重庆市长寿区人民医院进行治疗的脑梗死患者98例,根据治疗方案的差别分为对照组(49例)和治疗组(49例)。对照组患者静脉滴注单唾液酸四己糖神经节苷脂钠注射液,60 mg加入生理盐水250 m L中,1次/d。治疗组在对照组的基础上口服血栓心脉宁胶囊,4粒/次,3次/d。两组患者均连续治疗4周。比较治疗前后两组患者临床疗效、神经功能缺损评分和神经功能指标差异。结果治疗后,对照组患者的总有效率为79.59%,显著低于治疗组的95.92%,两组比较差异有统计学意义(P0.05)。治疗后,两组患者神经功能缺损评分均明显降低,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组上述评分改善情况显著好于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组血清神经元特异性烯醇化酶(NSE)、血红素氧合酶-1(HO1)、S100β水平均明显降低,胰岛素样生长因子-1(IGF-1)水平升高,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组患者上述指标比对照组改善更显著,两组比较差异具有统计学意义(P0.05)。结论血栓心脉宁胶囊联合单唾液酸四己糖神经节苷脂治疗脑梗死效果显著,可明显改善患者神经功能,具有一定的临床推广应用价值。

Clinical study on Xueshuan Xinmaining Capsules combined with onosialotetrahexosylganglioside in treatment of cerebral infarction

Objective To investigate the clinical effect of Xueshuan Xinmaining Capsules combined with onosialotetrahexosyl- ganglioside in treatment of cerebral infarction.Methods Patients (98 cases) with cerebral infarction in People's Hospital of Changshou Chongqing from September 2015 to September 2016 were divided into control (49 cases) and treatment (49 cases) groups based on different treatments. Patients in the control group were ivadministered with Monosialotetrahexosylganglioside Sodium Injection, 60 mg added into 250 mL normal saline, once daily. Patients in the treatment group werepoadministered with Xueshuan Xinmaining Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the differences of clinical efficacy, neurological deficit score, and nerve function in two groups before and after treatment were compared.Results After treatment, the clinical efficacy in the control group was 79.59%, which was significantly lower than 95.92% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the neurological deficit scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the score in the treatment group was significantly better than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the serum NSE, HO1 and S100β levels in two groups were significantly decreased, but IGF-1 level was significantly increased, and there were differences in the same group (P < 0.05). And the indexes in the treatment group were improved more significantly than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Xueshuan Xinmaining Capsules combined with onosialotetrahexosylganglioside has significant effect in treatment of cerebral infarction, and can obviously improve the neurological function, which has a certain clinical application value.